Silicon Valley Elites Bet Big on Embryo Genetic Testing: Predicting Disease Risk Sparks Controversy

Over the last five years, tech giants like Anne Wojcicki, Sam Altman, and others have invested millions in direct-to-consumer polygenic testing startups such as Orchid, Nucleus, and Genomic Prediction, sparking controversy. For a few thousand dollars, these companies screen embryos, analyze DNA, and estimate the risk of developing conditions like addiction and obesity, even predicting IQ. Unlike tests for single-gene diseases, these services focus on polygenic diseases like type 2 diabetes and inflammatory bowel disease, providing parents with online reports assessing each embryo's genetic risk. This practice, while popular among Silicon Valley elites, faces widespread scientific skepticism.